EYPT
EYPT
NASDAQ · Pharmaceuticals

Eyepoint Inc

$13.23
-0.56 (-4.06%)
As of Mar 22, 10:12 PM ET ·
Financial Highlights (FY 2026)
Revenue
61.99M
Net Income
-187,473,367
Gross Margin
91.4%
Profit Margin
-302.4%
Rev Growth
+5.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 91.4% 91.4% 35.0% 35.0%
Operating Margin -337.1% -303.4% 22.3% 21.7%
Profit Margin -302.4% -287.3% 24.9% 20.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 61.99M 58.80M 211.34M 213.20M
Gross Profit 56.67M 53.75M 73.87M 74.52M
Operating Income -208,929,101 -178,368,612 47.20M 46.31M
Net Income -187,473,367 -160,051,252 52.60M 44.43M
Gross Margin 91.4% 91.4% 35.0% 35.0%
Operating Margin -337.1% -303.4% 22.3% 21.7%
Profit Margin -302.4% -287.3% 24.9% 20.8%
Rev Growth +5.4% +5.4% -6.2% +21.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 107.95M 96.71M
Total Equity 420.20M 423.48M
D/E Ratio 0.26 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -206,732,009 -186,298,054 60.54M 58.90M
Free Cash Flow 38.74M 42.58M